Please use this identifier to cite or link to this item:
http://dspace.bits-pilani.ac.in:8080/jspui/handle/123456789/13852
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Sundriyal, Sandeep | - |
dc.date.accessioned | 2024-01-17T04:44:28Z | - |
dc.date.available | 2024-01-17T04:44:28Z | - |
dc.date.issued | 2022-10 | - |
dc.identifier.uri | https://www.sciencedirect.com/science/article/pii/S0960894X12010013 | - |
dc.identifier.uri | http://dspace.bits-pilani.ac.in:8080/jspui/xmlui/handle/123456789/13852 | - |
dc.description.abstract | Bacterial resistance to β-lactam antibiotics caused by class B metallo-β-lactamases (MBL), especially for certain hospital-acquired, Gram-negative pathogens, poses a significant threat to public health. We report several 2-substituted 4,5-dihydrothiazole-4-carboxylic acids to be novel MBL inhibitors. Structure activity relationship (SAR) and molecular modeling studies were performed and implications for further inhibitor design are discussed. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Elsevier | en_US |
dc.subject | Pharmacy | en_US |
dc.subject | Metallo-β-lactamase | en_US |
dc.subject | Inhibitor | en_US |
dc.subject | Rational design | en_US |
dc.subject | Molecular modeling | en_US |
dc.title | 2-Substituted 4,5-dihydrothiazole-4-carboxylic acids are novel inhibitors of metallo-β-lactamases | en_US |
dc.type | Article | en_US |
Appears in Collections: | Department of Pharmacy |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.